SCHEMBL2834231

SCHEMBL2834231

NC(c1ccc(Cl)cc1)C(O)c1ccc(-c2ccncc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 5/20 0.50
CYP19A1 P11511 3/20 0.47
GCGR P47871 1/20 0.43
PRCP P42785 1/20 0.42
CYP17A1 P05093 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP11B1 P15538 1/20 0.42
CYP11B2 P19099 1/20 0.42
LSS P48449 1/20 0.41
DPP4 P27487 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
LMNA P02545 2/20 0.38
KDM4E B2RXH2 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
ROCK2 O75116 1/20 0.37
PRKACA P17612 1/20 0.37
RPS6KB1 P23443 1/20 0.37
IRAK1 P51617 1/20 0.37
PRKX P51817 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7809316 1.00 AKT1 (0.50) AKT1CYP19A1GCGRPRCPCYP17A1
SCHEMBL2834054 0.84 CYP19A1 (0.46) AKT1CYP19A1PRCPCYP3A4ROCK2
SCHEMBL7809471 0.84 CYP19A1 (0.46) AKT1CYP19A1PRCPCYP3A4ROCK2
SCHEMBL19598258 0.84 ADRB2 (0.50) CYP3A4LMNAADRB2
SCHEMBL15989837 0.84 ADRB2 (0.50) CYP3A4LMNAADRB2
SCHEMBL24645195 0.84 ADRB2 (0.50) CYP3A4LMNAADRB2
SCHEMBL15989839 0.84 ADRB2 (0.50) CYP3A4LMNAADRB2
SCHEMBL2839284 0.83 CYP19A1 (0.46) CYP19A1CYP17A1CYP3A4RAB9A
SCHEMBL7803951 0.83 CYP19A1 (0.46) CYP19A1CYP17A1CYP3A4RAB9A
Hydrochloric Acid SCHEMBL2838936 0.82 CYP19A1 (0.45) CYP19A1CYP17A1CYP3A4RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP claimed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO claimed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US claimed
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 AKT1 2813/4885CYP19A1 1427/4885GCGR 558/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 AKT1 2813/4885CYP19A1 1427/4885GCGR 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.